Breast cancer therapy offers hope for patients at risk of recurrence
News
Grifols collaborates with startup FcR Therapeutics to develop autoimmune therapies
Partnership aims to create recombinant nanobodies to treat immune disorders
Algiax announces results from phase 2a trial for neuropathic pain treatment
Study shows AP-325 offers lasting pain relief without central side effects
Aplagon secures EUR 7 million for APAC phase 2a trials
Funding led by new investors FSG and EIC Fund
CHMP recommends SC Rybrevant for EGFR-mutated NSCLC patients
Positive opinion issued for marketing authorisation extension
Cartesian Therapeutics announces FDA agreement for new trial
Phase 3 trial of Descartes-08 in myasthenia gravis to start in 1H25
FDA approves new Alzheimer’s treatment regimen
Patients and care partners may find once every four weeks maintenance dosing easier
Vedanta Biosciences reveals Phase 2 VE303 results
Study highlights VE303’s potential in reducing recurrent CDI
Alligator Bioscience reports survival benefit of mitazalimab with mFOLFIRINOX
Comparison shows improved survival rates for pancreatic cancer treatment
Zydus announces USFDA Orphan Drug Designation for Usnoflast in ALS treatment
Orphan drug designation offers development incentives and potential market exclusivity
Tris Pharma announces positive results from ALLEVIATE-1 trial of cebranopadol
Phase 3 trial shows promising pain relief for acute pain patients
Innovative Health Initiative launches a trial aimed at ending Crohn’s Disease
Europe’s first biomarker trial seeks to prevent Crohn’s Disease onset
AstraZeneca receives positive recommendations for lung cancer treatments
NICE endorses Imfinzi and Tagrisso for enhanced lung cancer care
AlzeCure’s NeuroRestore ACD856 to be presented at AD/PD 2025
Preclinical data highlights potential in treating Alzheimer’s disease
EC approves lazertinib in combination with amivantamab for NSCLC patients
Combination therapy shows superior survival benefit over standard treatment
